


Framework for the evaluation of new tests for **tuberculosis infection**



Framework for the evaluation of new tests for **tuberculosis infection**



Framework for the evaluation of new tests for tuberculosis infection

ISBN 978-92-4-000718-5 (electronic version)

ISBN 978-92-4-000719-2 (print version)

© World Health Organization 2020

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition."

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. (<http://www.wipo.int/amc/en/mediation/rules/>)

Suggested citation. Framework for the evaluation of new tests for tuberculosis infection. Geneva: World Health Organization; 2020. Licence: CC BY-NC-SA 3.0 IGO.

Cataloguing-in-Publication (CIP) data. CIP data are available at <http://apps.who.int/iris>.

Sales, rights and licensing. To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

Editing and design by Inis Communication

Contents

Acknowledgements	v
Abbreviations	vi
Background	1
Scope.....	3
Document development process.....	3
Framework for evaluation of new tests for tuberculosis infection	4
Study design and population.....	5
Sample size calculation.....	7
Study analysis.....	9
Technical issues.....	10
Evaluation of safety for skin tests.....	14
Economic evaluation.....	14
Operational characteristics.....	17
References	18
Annex 1	19
Annex 2	20

Acknowledgements

This document was prepared by Yohhei Hamada (Research Institute of Tuberculosis, Japan) and Alberto Matteelli (University of Brescia, Italy), with input from a technical expert group comprising the following participants:

New Diagnostics Working Group, Stop TB Partnership, Geneva, Switzerland: Daniela Cirillo, Alberto Matteelli, with support from Karishma Saran in her capacity as Secretariat, New Diagnostics Working Group.

Foundation for Innovative New Diagnostics (FIND), Geneva, Switzerland: Adam Penn-Nicholson, Morten Ruhwald.

McGill University, Montreal, Canada: Dick Menzies, Olivia Oxlade.

World Health Organization Global TB Programme, Geneva, Switzerland: Saskia den Boon, Dennis Falzon, Avinash Kanchar, Alexei Korobitsyn, Matteo Zignol.

The technical working group used a consensus-building process to develop the document.

The participants in the external review group were Sevim Ahmedov, Claudia Denkinger, Darragh Duffy, Nazir Ismail, Afrânio Kritski, Elisa Nemes and Molebogeng X. Rangaka.

Abbreviations

ART	antiretroviral treatment
BCG	bacille Calmette–Guérin
CV	coefficient of variation
CXR	chest radiography
ELISA	enzyme-linked immunosorbent assay
HIV	human immunodeficiency virus
IGRA	interferon-gamma release assay
LLoQ	lower limit of quantification
LoD	limit of detection
PLHIV	people living with HIV
SD	standard deviation
TB	tuberculosis
TPT	TB preventive treatment
TST	tuberculin skin test
WHO	World Health Organization

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_24478

